- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03354663
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation (TactiSense)
Multi-Center Acute Safety Trial of TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia
- Royal Adelaide Hospital
-
Adelaide, Australia, 5000
- Ashford Hospital
-
Melbourne, Australia, 3050
- Royal Melbourne Hospital - City Campus
-
-
-
-
-
Dresden, Germany, 01307
- Herzzentrum Dresden GmbH Universitätsklinik
-
-
Saxony
-
Leipzig, Saxony, Germany, 04289
- Herzzentrum Leipzig GmbH
-
-
-
-
-
Milan, Italy, 20138
- Centro Cardiologico Monzino
-
-
Lombardy
-
Milan, Lombardy, Italy, 20132
- Ospedale San Raffaele
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Arkansas Heart Hospital
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Health
-
Redwood City, California, United States, 94062
- Sequoia Hospital
-
-
Colorado
-
Littleton, Colorado, United States, 80120
- South Denver Cardiology Associates, P.C.
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
Florida
-
Orlando, Florida, United States, 32803
- Florida Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Central Baptist Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10016
- New York University Hospital
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Austin, Texas, United States, 78705
- Texas Cardiac Arrhythmia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Plans to undergo a catheter ablation procedure due to symptomatic PAF that is refractory or intolerant to at least one Class I or III antiarrhythmic drug
- Physician's note indicating recurrent self-terminating AF
- One electrocardiographically documented AF episode within 6 months prior to the index ablation procedure
- At least 18 years of age
- Able and willing to comply with all trial requirements
- Informed of the nature of the trial, agreed to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.
Exclusion Criteria:
- Persistent or long-standing persistent atrial fibrillation (AF)
- Four or more cardioversions in the past 12 months
- Active systemic infection
- Known presence of cardiac thrombus
- Implanted with implantable cardiac defibrillator (ICD)
- Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, and other major surgical procedures in the preceding 3 months
- Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 3 months
- Left atrial diameter > 5.0 cm
- Left ventricular ejection fraction < 35%
- New York Heart Association (NYHA) class III or IV
- Previous left atrial surgical or catheter ablation procedure
- Left atrial surgical procedure or incision with resulting scar
- Previous tricuspid or mitral valve replacement or repair
- Heart disease in which corrective surgery is anticipated within 6 months
- Bleeding diathesis or suspected procoagulant state
- Contraindication to long term antithromboembolic therapy
- Presence of any condition that precludes appropriate vascular access
- Renal failure requiring dialysis
- Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
- Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- Pregnant or nursing
- Presence of other anatomic or comorbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results
- Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial
- Patient is unlikely to survive the protocol follow up period of 12 months
- Body mass index > 40 kg/m2
- Vulnerable subject
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TactiCath SE
Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
|
Ablation to achieve pulmonary vein isolation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Serious Adverse Events
Time Frame: 30 days
|
The primary safety endpoint is the rate of device or procedure-related serious adverse events occurring within 7 days of the index procedure. SAEs related solely to arrhythmia recurrence (without coexisting conditions such as thromboembolism, worsening heart failure, etc.) will not be considered primary safety endpoint events. The SAEs that will be included in this endpoint are:
Atrial-esophageal fistula, cardiac perforation/tamponade, and pulmonary vein stenosis that occur >7 days post procedure through 30 days will also contribute to the primary endpoint. |
30 days
|
Number of Participants With Procedural Success
Time Frame: 0 days
|
The primary effectiveness endpoint is acute procedural success, where acute procedural success is defined as confirmation of entrance block in all pulmonary veins
|
0 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Power Delivered
Time Frame: During Procedure
|
This outcome is the average power delivered for a case.
|
During Procedure
|
Index Cases Achieving ≥ 90% Lesions With ≥ 10 Contact Force
Time Frame: 0 days
|
Proportion of index cases achieving ≥ 90% lesions with ≥10g contact force
|
0 days
|
Number of Participants Experiencing Serious Adverse Events Within 30 Days
Time Frame: 30 days
|
Serious adverse events and adverse events related to the procedure and/or ablation catheter through 30 days post index ablation.
This excludes the events identified in the primary safety endpoint.
|
30 days
|
Number of Participants Experiencing a Serious Adverse Event Within 1 Year
Time Frame: 1 year
|
Serious adverse events and adverse events related to the procedure and/or ablation catheter through 1 year post index ablation
|
1 year
|
One-year Freedom From AF
Time Frame: 1 year
|
One-year freedom from AF, defined as freedom from symptomatic AF, atrial flutter (AFL), and atrial tachycardia (AT) lasting longer than 30 seconds through 9 months of follow-up after a 3-month blanking period.
|
1 year
|
One-year Drug-free Success From AF
Time Frame: 1 year
|
One-year drug-free success defined as freedom from any AF/AFL/AT lasting at least 30 seconds or any Class I or III AAD after removal from antiarrhythmic drug therapy as assessed from the end of the 3-month blanking period to 12 months following the ablation procedure.
|
1 year
|
Changes in EQ-5D-5L Utility Scores
Time Frame: 1 year
|
Changes in EQ-5D-5L utility scores from baseline to follow up at 3, 6, and 12 months Utility scores range from 0 (worst) to 1 (best).
A positive change indicates an improvement.
|
1 year
|
Changes in AFEQT Scores
Time Frame: 1 year
|
Changes in AFEQT scores from baseline to follow up at 3, 6, and 12 months AFEQT scores range from 0 (most severe symptoms) to 100 (no limitation or disability).
A positive change indicates an improvement in AF condition.
|
1 year
|
Health Care Utilization
Time Frame: 1 year
|
Cardiovascular-related health care utilization through 12 months post index ablation Cardiovascular-related health care utilization would include any office visits, tests, hospitalizations, or other interventions outside of routine follow up.
|
1 year
|
Force Time Integral (FTI)
Time Frame: 0 days
|
Mean force-time integral across lesions for a subject FTI for a lesion is the product of contact force in grams and duration of radiofrequency ablation in seconds.
The mean value for this product across all lesions for a subject is then calculated.
|
0 days
|
Average Catheter Temperature
Time Frame: 0 days
|
This outcome is the average temperature (by lesion) for a case.
|
0 days
|
Number of Participants With Recommended Irrigation Flow Rate Used During Procedure
Time Frame: 0 days
|
This outcome is whether or not the recommended irrigation flow rate was used for a case.
|
0 days
|
Contact Force During Procedure
Time Frame: 0 days
|
This outcome is the average contact force for a case.
|
0 days
|
Total Procedure Time
Time Frame: 0 days
|
This outcome is the total procedure time for a case.
|
0 days
|
Ablation Time - First to Last Ablation
Time Frame: 0 Days
|
This outcome is the total ablation time for a case.
This is the time from first to last ablation.
|
0 Days
|
Fluoroscopy Time
Time Frame: 0 days
|
This outcome is the total fluoroscopy time for a case.
|
0 days
|
Radiofrequency (RF) Application Time
Time Frame: 0 days
|
This outcome is the total RF application time for a case.
|
0 days
|
Number of Participants Using AutoMark
Time Frame: 0 days
|
This outcome is the number of cases using AutoMark.
|
0 days
|
Lesion Index (LSI)
Time Frame: 0 days
|
Mean lesion index (LSI) across lesions by subject Lesion index is a proprietary score calculated as a function of power, contact force, and duration for a radiofrequency (RF) energy application. Scores start at 0 (no ablation) and do not have an upper limit. Applications must be at least 6 seconds in duration to generate a score. Lesion index is intended to provide feedback to the operator during an RF application. |
0 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kristin Ruffner, PhD MBA, Abbott
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SJM-CIP-10216
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paroxysmal Atrial Fibrillation
-
Medtronic Cardiac Rhythm and Heart FailureCompletedParoxysmal Atrial Fibrillation (PAF)United States, Canada
-
Biosense Webster, Inc.Active, not recruitingRefractory Paroxysmal Atrial FibrillationChina
-
Boston Scientific CorporationCompletedParoxysmal Atrial Fibrillation (PAF)United States, Spain, Germany, Australia, United Kingdom, Sweden, Czechia, France, Portugal
-
Biosense Webster, Inc.RecruitingDrug Refractory Paroxysmal Atrial FibrillationUnited States
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchTerminatedSymptomatic Paroxysmal Atrial FibrillationGermany
-
Hospital Clinic of BarcelonaCompletedDrug-refractory Paroxysmal Atrial FibrillationSpain
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Biosense Webster, Inc.CompletedDrug Refractory Symptomatic Paroxysmal Atrial FibrillationUnited States
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Atrial Fibrillation SolutionsCompletedSymptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart DiseasesNetherlands, Australia, France, Norway, Germany, Croatia, Italy, Argentina, Belgium
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
Clinical Trials on TactiCath SE
-
Abbott Medical DevicesTerminatedPersistent Atrial FibrillationTaiwan, Singapore, Korea, Republic of, Hong Kong, Thailand
-
Abbott Medical DevicesCompletedParoxysmal Atrial FibrillationUnited States
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial Fibrillation | Paroxysmal Atrial FibrillationUnited States, France, Italy, Canada, Czechia
-
Fatebenefratelli HospitalFederico II University; Federal University of Rio Grande do Sul; Royal Brompton... and other collaboratorsRecruitingCoronary Artery Disease | Heart Failure | Aortic Valve Disease | Pulmonary Arterial Hypertension | Tetralogy of Fallot | Hypertrophic Cardiomyopathy | Athletes HeartItaly
-
Boston VA Research Institute, Inc.Agency for Healthcare Research and Quality (AHRQ)Completed
-
IDRIRockefeller UniversityCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of California, San FranciscoCompletedExperimental Condition TCT | Controlled Condition CGUnited States
-
Abbott Medical DevicesEndosenseCompletedAtrial Fibrillation | Tachycardia, Supraventricular